WO2003100427A1 - Method for identification of a ligand whereby receptor residence time is measured - Google Patents

Method for identification of a ligand whereby receptor residence time is measured Download PDF

Info

Publication number
WO2003100427A1
WO2003100427A1 PCT/IB2003/002023 IB0302023W WO03100427A1 WO 2003100427 A1 WO2003100427 A1 WO 2003100427A1 IB 0302023 W IB0302023 W IB 0302023W WO 03100427 A1 WO03100427 A1 WO 03100427A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
ccr5
ligand
residence time
compound
Prior art date
Application number
PCT/IB2003/002023
Other languages
English (en)
French (fr)
Inventor
Patrick Karl Dorr
Manoussos Perros
Graham Anthony Rickett
Original Assignee
Pfizer Limited
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211923A external-priority patent/GB0211923D0/en
Application filed by Pfizer Limited, Pfizer Inc. filed Critical Pfizer Limited
Priority to BR0309982-2A priority Critical patent/BR0309982A/pt
Priority to CA002485825A priority patent/CA2485825A1/en
Priority to JP2004507833A priority patent/JP2005533999A/ja
Priority to AU2003230129A priority patent/AU2003230129A1/en
Priority to EP03722972A priority patent/EP1506405A1/en
Priority to MXPA04011577A priority patent/MXPA04011577A/es
Publication of WO2003100427A1 publication Critical patent/WO2003100427A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/IB2003/002023 2002-05-23 2003-05-14 Method for identification of a ligand whereby receptor residence time is measured WO2003100427A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0309982-2A BR0309982A (pt) 2002-05-23 2003-05-14 Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
CA002485825A CA2485825A1 (en) 2002-05-23 2003-05-14 Method for identification of a ligand whereby receptor residence time is measured
JP2004507833A JP2005533999A (ja) 2002-05-23 2003-05-14 受容体滞留時間を測定するリガンドの同定方法
AU2003230129A AU2003230129A1 (en) 2002-05-23 2003-05-14 Method for identification of a ligand whereby receptor residence time is measured
EP03722972A EP1506405A1 (en) 2002-05-23 2003-05-14 Method for identification of a ligand whereby receptor residence time is measured
MXPA04011577A MXPA04011577A (es) 2002-05-23 2003-05-14 Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0211923A GB0211923D0 (en) 2002-05-23 2002-05-23 Method
GB0211923.8 2002-05-23
GB0309392.9 2003-04-24
GB0309392 2003-04-24

Publications (1)

Publication Number Publication Date
WO2003100427A1 true WO2003100427A1 (en) 2003-12-04

Family

ID=29585818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002023 WO2003100427A1 (en) 2002-05-23 2003-05-14 Method for identification of a ligand whereby receptor residence time is measured

Country Status (7)

Country Link
EP (1) EP1506405A1 (ja)
JP (1) JP2005533999A (ja)
AU (1) AU2003230129A1 (ja)
BR (1) BR0309982A (ja)
CA (1) CA2485825A1 (ja)
MX (1) MXPA04011577A (ja)
WO (1) WO2003100427A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3343220A1 (en) * 2016-12-27 2018-07-04 IMEC vzw Bioparticle characterization and identification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DISSE B ET AL: "BA 679 BR, A NOVEL LONG-ACTING ANTICHOLINERGIC BRONCHODILATOR", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 52, no. 5/6, 1993, pages 537 - 544, XP008002589, ISSN: 0024-3205 *
KUKKONEN JYRKI P ET AL: "Different apparent modes of inhibition of alpha-2A-adrenoceptor by alpha-2-adrenoceptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 335, no. 1, 1997, pages 99 - 105, XP002258102, ISSN: 0014-2999 *
MARKGREN PER-OLOF ET AL: "Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology", ANALYTICAL BIOCHEMISTRY, vol. 291, no. 2, 15 April 2001 (2001-04-15), pages 207 - 218, XP002258104, ISSN: 0003-2697 *
MIYOSHI KAZUHISA ET AL: "Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 355, no. 1, 1997, pages 119 - 125, XP002258103, ISSN: 0028-1298 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3343220A1 (en) * 2016-12-27 2018-07-04 IMEC vzw Bioparticle characterization and identification
US10705083B2 (en) 2016-12-27 2020-07-07 Imec Vzw Bioparticle characterization and identification using interface thermal resistance measurement during bioparticle adhesion and detachment

Also Published As

Publication number Publication date
AU2003230129A1 (en) 2003-12-12
CA2485825A1 (en) 2003-12-04
MXPA04011577A (es) 2005-03-07
JP2005533999A (ja) 2005-11-10
BR0309982A (pt) 2005-03-22
EP1506405A1 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
Biron et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action
Bray et al. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum: a correlation of chloroquine sensitivity with energy-dependent drug accumulation
Al-Aoukaty et al. MIP-3alpha, MIP-3beta and fractalkine induce the locomotion and the mobilization of intracellular calcium, and activate the heterotrimeric G proteins in human natural killer cells.
Raymond et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage
Kim et al. Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method
Muniz-Medina et al. The relative activity of “function sparing” HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
Calado et al. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor
Guzzo et al. The CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1
McLEOD et al. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay
Saladini et al. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients
DK2678683T3 (en) METHOD FOR forecasting PROGRESSION OF HIV DISEASE
WO2003100427A1 (en) Method for identification of a ligand whereby receptor residence time is measured
US20040023845A1 (en) Method for identifying CCR5 receptor antagonists by measuring residency time
WO2000043551A1 (en) Determining viral load in double negative t cells
JP6206953B2 (ja) 成人ｔ細胞白血病の発症し易さを試験する方法
Ouellet et al. Effect of galectins on viral transmission
JP5434599B2 (ja) 抑肝散のバイオアッセイ方法
Zhao et al. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4
Giménez-Barcons et al. Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection
Tripathi et al. Basigin interacts with majority of the erythrocyte binding Pvfam ‘a’family proteins of Plasmodium vivax to assist parasite entry into host cell
Wanjalla et al. Digital spatial profiling of coronary plaques from persons living with HIV reveals high levels of STING and CD163 in macrophage enriched regions
Gutiérrez-Iñiguez et al. CD56Bright NK Cell Expansion and Low Expression of Cytotoxic Molecules in CD56Dim NK Cells in HIV/HCV Coinfected Patients
Udensi et al. Leucocyte phagocytic activity of treatment-naïve HIV positive patients in Umuahia, Nigeria.
Vinutha Hematological Profile of HIV Patients and its Relation to CD4 Cell Count
Lundberg Studies of granulocyte colony stimulating factor signaling to develop tools for clinical assessments of severe congenital neutropenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003722972

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2485825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004507833

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003722972

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003722972

Country of ref document: EP